MX393600B - Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). - Google Patents
Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).Info
- Publication number
- MX393600B MX393600B MX2019010643A MX2019010643A MX393600B MX 393600 B MX393600 B MX 393600B MX 2019010643 A MX2019010643 A MX 2019010643A MX 2019010643 A MX2019010643 A MX 2019010643A MX 393600 B MX393600 B MX 393600B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- compositions
- mitogen
- forms
- protein kinase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 title 2
- 101710166115 Mitogen-activated protein kinase 2 Proteins 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124789 MK2 inhibitor Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472015P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022543 WO2018170199A1 (en) | 2017-03-16 | 2018-03-15 | Forms and compositions of a mk2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010643A MX2019010643A (es) | 2019-10-17 |
| MX393600B true MX393600B (es) | 2025-03-24 |
Family
ID=63522534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010643A MX393600B (es) | 2017-03-16 | 2018-03-15 | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10882867B2 (https=) |
| EP (1) | EP3595658A4 (https=) |
| JP (2) | JP2020514360A (https=) |
| CN (1) | CN110678178B (https=) |
| AU (1) | AU2018236286B2 (https=) |
| CA (1) | CA3054823A1 (https=) |
| MX (1) | MX393600B (https=) |
| WO (1) | WO2018170199A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US11230551B2 (en) | 2017-03-16 | 2022-01-25 | Celgene Car Llc | Deuterated analogs of MK2 inhibitors and uses thereof |
| JP7282039B2 (ja) | 2017-03-16 | 2023-05-26 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体 |
| JP7200120B2 (ja) | 2017-03-16 | 2023-01-06 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤として有用なヘテロアリール化合物 |
| WO2018170204A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| CN114364681A (zh) * | 2019-05-17 | 2022-04-15 | 西建卡尔有限责任公司 | 治疗mk2介导的病症的方法 |
| KR20230142529A (ko) | 2021-02-01 | 2023-10-11 | 셀진 코포레이션 | Mk2 억제제, 이의 합성, 및 이의 중간체 |
| MX2024008704A (es) | 2022-01-14 | 2024-07-22 | Shanghai Hansoh Biomedical Co Ltd | Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este. |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0894003A4 (en) * | 1996-04-12 | 2000-10-04 | Bristol Myers Squibb Co | N-FORMYL HYDROXYLAMINE-BASED COMPOUNDS SUITABLE AS INCEPTIENTS OF THE ACE ENZYME AND / OR ENDOPEPTIDASE NEP |
| CN1747949A (zh) * | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US7790712B2 (en) * | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| CN101360750A (zh) * | 2005-11-23 | 2009-02-04 | 英特芒尼公司 | 应激活化蛋白激酶系统的调节方法 |
| CN101687869A (zh) | 2007-07-16 | 2010-03-31 | 诺瓦提斯公司 | 作为mk2抑制剂的四环内酰胺衍生物 |
| WO2011062765A2 (en) * | 2009-11-17 | 2011-05-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102464639A (zh) * | 2010-11-16 | 2012-05-23 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
| EP2699572B1 (en) * | 2011-04-21 | 2016-08-10 | Origenis GmbH | Heterocyclic compounds as kinase inhibitors |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| US9695193B2 (en) * | 2013-06-26 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds |
| WO2016032882A1 (en) * | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| RS62017B1 (sr) * | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| WO2016112292A1 (en) | 2015-01-08 | 2016-07-14 | Moerae Matrix, Inc. | Formulation of mk2 inhibitor peptides |
| JP7282039B2 (ja) | 2017-03-16 | 2023-05-26 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤、その合成、およびそれに至るまでの中間体 |
| WO2018170204A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
| US11230551B2 (en) | 2017-03-16 | 2022-01-25 | Celgene Car Llc | Deuterated analogs of MK2 inhibitors and uses thereof |
| JP7200120B2 (ja) | 2017-03-16 | 2023-01-06 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤として有用なヘテロアリール化合物 |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| CN114364681A (zh) | 2019-05-17 | 2022-04-15 | 西建卡尔有限责任公司 | 治疗mk2介导的病症的方法 |
| US20230255979A1 (en) | 2020-07-24 | 2023-08-17 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| KR20230142529A (ko) | 2021-02-01 | 2023-10-11 | 셀진 코포레이션 | Mk2 억제제, 이의 합성, 및 이의 중간체 |
-
2018
- 2018-03-15 US US16/494,725 patent/US10882867B2/en active Active
- 2018-03-15 CA CA3054823A patent/CA3054823A1/en active Pending
- 2018-03-15 MX MX2019010643A patent/MX393600B/es unknown
- 2018-03-15 WO PCT/US2018/022543 patent/WO2018170199A1/en not_active Ceased
- 2018-03-15 JP JP2019550652A patent/JP2020514360A/ja active Pending
- 2018-03-15 AU AU2018236286A patent/AU2018236286B2/en not_active Ceased
- 2018-03-15 EP EP18768155.6A patent/EP3595658A4/en not_active Withdrawn
- 2018-03-15 CN CN201880032086.2A patent/CN110678178B/zh not_active Expired - Fee Related
-
2020
- 2020-12-29 US US17/136,464 patent/US11629153B2/en active Active
-
2022
- 2022-10-27 JP JP2022172305A patent/JP2023017840A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020514360A (ja) | 2020-05-21 |
| WO2018170199A1 (en) | 2018-09-20 |
| CN110678178A (zh) | 2020-01-10 |
| US11629153B2 (en) | 2023-04-18 |
| CA3054823A1 (en) | 2018-09-20 |
| EP3595658A1 (en) | 2020-01-22 |
| EP3595658A4 (en) | 2020-11-25 |
| AU2018236286B2 (en) | 2022-02-17 |
| US10882867B2 (en) | 2021-01-05 |
| CN110678178B (zh) | 2023-10-03 |
| US20210198276A1 (en) | 2021-07-01 |
| US20200148701A1 (en) | 2020-05-14 |
| MX2019010643A (es) | 2019-10-17 |
| AU2018236286A1 (en) | 2019-09-19 |
| JP2023017840A (ja) | 2023-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393600B (es) | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). | |
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| CL2019003114A1 (es) | Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063) | |
| CL2022000027A1 (es) | Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257). | |
| EP3873477A4 (en) | CYCLIN DEPENDENT KINASE 7 (CDK7) INHIBITOR | |
| PH12021500026A1 (en) | Irak degraders and uses thereof | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| MX2017003359A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| CY1125582T1 (el) | Συνθεσεις και μεθοδοι για εκλυση μακρας διαρκειας των ανταγωνιστων της εκλυτικης ορμονης των γοναδοτροπινων (gnrh). | |
| WO2018081648A3 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
| MY195442A (en) | Anti-CD40 Antibodies and Their Uses | |
| EP3740206A4 (en) | INHIBITORS OF THE CYCLINE-DEPENDENT KINASE 7 (CDK7) | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MX391223B (es) | Aislado de proteina de maiz y metodos de manufacturacion del mismo. | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| EA202092692A1 (ru) | Аналоги рапамицина и их применения | |
| EA201891626A1 (ru) | Ингибиторы тирозинкиназы брутона |